Evidence map›Paper›PMID 29768213›Full record

ArticleCell reports2018

miRNAs that Induce Human Cardiomyocyte Proliferation Converge on the Hippo Pathway.

Marta Diez-Cuñado, Ke Wei, Paul J Bushway, Mano R Maurya, Ranjan Perera, Shankar Subramaniam, Pilar Ruiz-Lozano, Mark Mercola

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 99 citations in OpenAlex.

  1. Signaling pathways regulating cardiac regeneration.Cell regeneration (London, England) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Acta biochimica et biophysica Sinica · 2025
    Article
  12. Article
  13. Review
  14. Review
  15. Advances in Drug Discovery for Cardiomyocyte Proliferation.Current treatment options in cardiovascular medicine · 2025
    Review
  16. The molecular mechanisms of cardiac development and related diseases.Signal transduction and targeted therapy · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Marta Diez-CuñadoSanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Ke WeiSanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Translational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Paul J BushwaySanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA.
Mano R MauryaDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA; San Diego Supercomputer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Ranjan PereraSanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Shankar SubramaniamDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA; San Diego Supercomputer Center, University of California, San Diego, La Jolla, CA 92093, USA; Computer Science and Engineering, Cellular and Molecular Medicine, and Graduate Program in Bioinformatics, University of California, San Diego, La Jolla, CA 92093, USA.
Pilar Ruiz-LozanoSanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Stanford Cardiovascular Institute and Department of Medicine, Stanford, CA 94305, USA; Regencor, Inc., Los Altos, CA 92044, USA. Electronic address: pilar@regencor.com.
Mark MercolaSanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA; Stanford Cardiovascular Institute and Department of Medicine, Stanford, CA 94305, USA. Electronic address: mmercola@stanford.edu.
University of California, San Diego · USDiscovery Institute · USCardiovascular Institute of the South · USSanford Burnham Prebys Medical Discovery Institute · USShanghai East Hospital · CN

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
Systems Biology Analyses for Hemodynamic Regulation of Vascular HomeostasisR01HL108735 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHIEN, SHU, SHYY, JOHN YJ · 2012 to 2024
$13.4M
Shear Regulation of MicroRNA Transportomes and Targetomes in Vascular HomeostasisR01HL106579 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHIEN, SHU, SHYY, JOHN YJ · 2011 to 2022
$8.3M
MicroRNA Control of Dilated CardiomyopathyR01HL130840 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Shankar Subramaniam · 2016 to 2026
$4.6M
GENETIC ABLATION OF EPICARDIAL FUNCTION IN THE MOUSER01HL065484 · NHLBI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RUIZ-LOZANO, PILAR · 2002 to 2012
$3.7M
San Diego Skeletal Muscle Research CenterP30AR061303 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, JU · 2011 to 2015
$3.3M
Role of miR25 in Heart FailureR01HL128072 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAJJAR, ROGER J., MERCOLA, MARK · 2015 to 2018
$2.5M
microRNAs and Integrative Control on Cardiopoiesis - CHANGE OF GRANTEE INSTITUTIOR01HL113601 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MERCOLA, MARK · 2012 to 2016
$2.2M
Small Molecule NOTCH Inhibitors for the treatment of pulmonary hypertensionR01HL132225 · NHLBI · STANFORD UNIVERSITY · PI MERCOLA, MARK, THISTLETHWAITE, PATRICIA A · 2016 to 2019
$1.7M
Genetic Rescue of Retinoid-Induced DysfunctionR01HL086879 · NHLBI · STANFORD UNIVERSITY · PI RUIZ-LOZANO, PILAR · 2009 to 2013
$1.7M
NCI NIH HHS P30 CA030199NHLBI NIH HHS R01 HL065484NHLBI NIH HHS R01 HL086879NHLBI NIH HHS R01 HL106579NHLBI NIH HHS R01 HL108735NHLBI NIH HHS R01 HL113601NHLBI NIH HHS R01 HL128072NHLBI NIH HHS R01 HL130840NHLBI NIH HHS R01 HL132225NIAMS NIH HHS P30 AR061303
6 · The paper itself

Abstract

Understanding the mechanisms that control human cardiomyocyte proliferation might be applicable to regenerative medicine. We screened a whole genome collection of human miRNAs, identifying 96 to be capable of increasing proliferation (DNA synthesis and cytokinesis) of human iPSC-derived cardiomyocytes. Chemical screening and computational approaches indicated that most of these miRNAs (67) target different components of the Hippo pathway and that their activity depends on the nuclear translocation of the Hippo transcriptional effector YAP. 53 of the 67 miRNAs are present in human iPSC cardiomyocytes, yet anti-miRNA screening revealed that none are individually essential for basal proliferation of hiPSC cardiomyocytes despite the importance of YAP for proliferation. We propose a model in which multiple endogenous miRNAs redundantly suppress Hippo signaling to sustain the cell cycle of immature cardiomyocytes.

Indexed as

Signal TransductionCell DivisionCell ProliferationCulture Media, ConditionedDNAHumansInduced Pluripotent Stem CellsMicroRNAsMyocytes, CardiacProtein Serine-Threonine KinasesCulture Media, ConditionedDNAMicroRNAsProtein Serine-Threonine KinasesHippo pathwayhuman cardiomyocytesiPSCsmicroRNAsproliferation

Identifiers

PMID29768213
PMCPMC6261450
OpenAlexW2804913208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.